Research Article
BibTex RIS Cite

Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings

Year 2023, Volume: 50 Issue: 1, 37 - 43, 19.03.2023
https://doi.org/10.5798/dicletip.1266709

Abstract

Aim: This study investigates serum interleukin(IL)-37 levels in patients with systemic sclerosis (SS) and assesses its relationship with clinical findings.
Methods: This study included 35 patients with SS and 30 healthy control subjects. The demographic and clinical characteristics of the patients, such as the presence of Raynaud’s phenomenon, SS subtype, digital ulcers, gastrointestinal and lung involvement, and disease activity, were recorded. The medications used by the patients were recorded, and Serum IL-37 levels were measured using an enzyme-linked immunosorbent assay. The United Kingdom Functional Scoring system was used to evaluate the functional status of the patients, while the Valentini criteria were used to evaluate disease activity. Skin involvement was evaluated based on the modified Rodnan skin score.
Results: Although serum IL-37 levels were found to be lower in patients with SS than in the control group, the difference was not statistically significant (p= 0.078). A negative correlation was identified between serum IL-37 levels and C3 levels in patients with SS (p= 0.046). No significant relationship was found between IL-37 levels and other clinical and laboratory parameters.
Conclusion: Unlike in patients with autoimmune disorders, serum IL-37 levels were found to be lower in patients with SS than in the control subjects, and IL-37 demonstrated a negative correlation with C3 levels.

References

  • 1. Cutolo M, Soldano S, Smith V.Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev ClinImmunol. 2019;15(7):753-64.
  • 2. Koca SS, Ozgen M, Isik A. Sistemik skleroz etiyopatogenezi. RAED Dergisi.2012;4:39-46.
  • 3. Asano Y. Systemic sclerosis J Dermatol. 2018;45(2):128-38.
  • 4. Denton CP, Khanna D.Systemic sclerosis. Lancet. 2017;390(10103):1685-99.
Year 2023, Volume: 50 Issue: 1, 37 - 43, 19.03.2023
https://doi.org/10.5798/dicletip.1266709

Abstract

References

  • 1. Cutolo M, Soldano S, Smith V.Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev ClinImmunol. 2019;15(7):753-64.
  • 2. Koca SS, Ozgen M, Isik A. Sistemik skleroz etiyopatogenezi. RAED Dergisi.2012;4:39-46.
  • 3. Asano Y. Systemic sclerosis J Dermatol. 2018;45(2):128-38.
  • 4. Denton CP, Khanna D.Systemic sclerosis. Lancet. 2017;390(10103):1685-99.
There are 4 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Original Articles
Authors

Turgut Bozan This is me

Remzi Cevik This is me

İbrahim Batmaz This is me

İbrahim Gündüz This is me

Abdullah Zübeyir Dagli This is me

Publication Date March 19, 2023
Submission Date October 12, 2022
Published in Issue Year 2023 Volume: 50 Issue: 1

Cite

APA Bozan, T., Cevik, R., Batmaz, İ., Gündüz, İ., et al. (2023). Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Tıp Dergisi, 50(1), 37-43. https://doi.org/10.5798/dicletip.1266709
AMA Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. March 2023;50(1):37-43. doi:10.5798/dicletip.1266709
Chicago Bozan, Turgut, Remzi Cevik, İbrahim Batmaz, İbrahim Gündüz, and Abdullah Zübeyir Dagli. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Tıp Dergisi 50, no. 1 (March 2023): 37-43. https://doi.org/10.5798/dicletip.1266709.
EndNote Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ (March 1, 2023) Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. Dicle Tıp Dergisi 50 1 37–43.
IEEE T. Bozan, R. Cevik, İ. Batmaz, İ. Gündüz, and A. Z. Dagli, “Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings”, diclemedj, vol. 50, no. 1, pp. 37–43, 2023, doi: 10.5798/dicletip.1266709.
ISNAD Bozan, Turgut et al. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Tıp Dergisi 50/1 (March 2023), 37-43. https://doi.org/10.5798/dicletip.1266709.
JAMA Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. 2023;50:37–43.
MLA Bozan, Turgut et al. “Serum Interleukin-37 Levels in Patients With Systemic Sclerosis and Its Relation With Clinical Findings”. Dicle Tıp Dergisi, vol. 50, no. 1, 2023, pp. 37-43, doi:10.5798/dicletip.1266709.
Vancouver Bozan T, Cevik R, Batmaz İ, Gündüz İ, Dagli AZ. Serum Interleukin-37 Levels in Patients with Systemic Sclerosis and its Relation with Clinical Findings. diclemedj. 2023;50(1):37-43.